Human leukocyte antigen molecule presenting private tumor-exclusive neoepitope peptide (HLA-presented tumor neoepitope (no widely accepted standard abbreviation; "HLA" is commonly used for human leukocyte antigen, but the full target as described does not have a universal abbreviation))

This target refers to any **human leukocyte antigen (HLA) molecule** that presents a **private**, i.e., patient-specific and tumor-exclusive, mutated peptide known as a **neoepitope**. These complexes arise from somatic mutations in cancer cells that generate novel peptides absent from normal tissues. When these mutant peptides bind to an individual's HLA molecules and are displayed on the cell surface, they can be recognized by autologous T cells as foreign—triggering an anti-tumor immune response. Such targets form the basis for highly personalized immunotherapies including neoantigen vaccines and adoptive transfer of neoantigen-reactive T cells[1][2]. However, this description encompasses many possible molecular entities rather than one defined protein or receptor; it represents an entire class of potential targets central to modern cancer immunotherapy research. If you need structured information about individual HLAs or specific identified peptide-HLA complexes used in therapy development, those should be specified more narrowly—for example "HLA-A*02:01 presenting mutant KRAS G12D peptide."

Other names

HLA-presented neoantigenTumor-specific HLA-peptide complexNeoepitope-HLA complex

Induction of anti-tumor immune response by enabling recognition of tumor cells by cytotoxic T lymphocytes through presentation of mutated peptides on HLA molecules[1][2].